Yankees Score with ...
Health Care: Drugs
Amarin Corporation PLC (AMRN: NASDAQ)
$6.78 -0.14 | -2.02%
05/24/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -582.00K |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 582.00K |
| Selling, General, and Administrative Expenses | 57.79M | 22.56M | 17.09M | 15.25M |
| Research & Development | 58.96M | 21.60M | 28.01M | 17.84M |
| Operating Income before D & A (EBITDA) | -116.75M | -44.16M | -45.10M | -32.50M |
| Depreciation & Amortization | 13.30M | 76.00K | 63.00K | 582.00K |
| Interest Income | 544.00K | 231.00K | 53.00K | 780.00K |
| Other Income - Net | -35.77M | -22.68M | -205.02M | 2.16M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -21.37M |
| Total Income Before Interest Expenses (EBIT) | -165.28M | -66.68M | -250.13M | -51.52M |
| Interest Expense | 18.09M | 1.00K | 19.00K | 8.23M |
| Pre-Tax Income | -183.37M | -66.69M | -250.15M | -59.76M |
| Income Taxes | 9.12M | 2.52M | -501.00K | -440.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -179.18M | -69.13M | -249.59M | -59.32M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -179.18M | -69.13M | -249.59M | -59.32M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -179.18M | -69.13M | -249.59M | -59.32M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-179.18M | -69.13M | -249.59M | -37.94M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -179.18M | -69.13M | -249.59M | -59.32M |
| Basic EPS from Continuing Ops. | -1.24 | -0.53 | -2.49 | -1.40 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.24 | -0.53 | -2.49 | -1.40 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.24 | -0.53 | -2.49 | -1.40 |
| Basic Normalized Net Income/Share | -1.24 | -0.53 | -2.49 | -0.90 |
| EPS fr Continuing Ops. | -1.24 | -0.53 | -2.49 | -1.40 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.24 | -0.53 | -2.49 | -1.40 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.24 | -0.53 | -2.49 | -1.40 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.24 | -0.53 | -2.49 | -0.90 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AMRN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Useralexr685
- ContributorDrugs Facing FDA Approval i...
- ContributorHigh Volume Technicals for ...
- ContributorBreakout Stocks Of The Week...
- UserHassan Portfolio
- Contributor4 Drug Stocks Facing FDA Ap...
- UserLividog
- ContributorStocks Rising On Unusual Vo...
- UserPharma
Latest AMRN Headlines from TheStreet
- Amarin Announces Approval Of Supplemental New Drug Application For Chemport As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier 04.18.13 | 06:04 am
- Amarin Announces New Clinical Data Showing Significant Reductions In Apolipoprotein C-III Levels In MARINE And ANCHOR Studies Of Vascepa(R) 04.08.13 | 06:04 am
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 3 Volatile Drug Stocks To Watch 04.01.13 | 03:04 pm
- Steve Rosenman Says Amarin Has Sticky Web Eyeballs! 03.27.13 | 04:03 pm
- Amarin's Sloooow Vascepa Launch 03.25.13 | 01:03 pm
- 'Mad Money' Lightning Round: Realogy Is Great, Cisco Terrific 03.22.13 | 06:03 am
- Cramer's 'Mad Money' Recap: It's Time to Pause 03.21.13 | 08:03 pm
- Keryx CEO vs. A Short Seller: Zerenex Patent Debate 03.13.13 | 07:03 am
Press Releases for AMRN
- Amarin To Present At The Deutsche Bank 26th Annual Healthcare Conference - PR Newswire 04.26.11 | 08:04 am
- Amarin's AMR101 Phase 3 ANCHOR Trial Meets All Primary And Secondary Endpoints With Statistically Significant Reductions In Triglycerides At Both 4 Gram And 2 Gram Doses And Statistically Significant Decrease In LDL-C - PR Newswire 04.18.11 | 02:04 am
- Phase 3 MARINE Trial Data To Be Presented In May At The National Lipid Association 2011 Annual Scientific Sessions - PR Newswire 04.05.11 | 08:04 am
- Amarin To Present At The 10th Annual Needham Healthcare Conference - PR Newswire 03.31.11 | 07:03 am
Partner Headlines for AMRN
- Amarin & Celsion: Post-Earnings Roundup - Seeking Alpha 05.15.13 | 09:05 am
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Stock Watch Tuesday, 8 January - Seeking Alpha 01.08.13 | 09:01 am
- Stock Watch Wednesday, 2 January - Seeking Alpha 01.02.13 | 08:01 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Pre-Market Most Active for Dec 7, 2012 : BAC, QQQ, NOK, AMRN, VNTV, AVGO, MEMP, AAPL, FB, SAN, C, FCX - NASDAQ 12.07.12 | 01:12 pm
